We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ANAGRELIDE GPPL, ANAGRELIDE NEO HEALTH, ANAGRELIDE HP, ANAGRELIDE NHPL, ANAGRELIDE APOTEX, ANAGRELIDE NEO (Neo Health (Australia) Pty Ltd)
Product name
ANAGRELIDE GPPL, ANAGRELIDE NEO HEALTH, ANAGRELIDE HP, ANAGRELIDE NHPL, ANAGRELIDE APOTEX, ANAGRELIDE NEO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
151 working days (255)
Active ingredients
Anagrelide hydrochloride
Registration type
New generic medicine
Indication
ANAGRELIDE GPPL, ANAGRELIDE NEO HEALTH, ANAGRELIDE HP, ANAGRELIDE NHPL, ANAGRELIDE APOTEX, ANAGRELIDE NEO (capsules) is indicated for the treatment of essential thrombocythaemia.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.